Company Profile: Plumb Pharmaceuticals
The problem with current opioid use disorder (OUD) medication-assisted treatment is that in between doses, individuals are more likely to relapse because they must willingly choose to take their next…
Category Archives: Biotech
Propeller Health to Distribute in Japan
Propeller Health announced today it will begin distributing in Japan through collaboration with Novartis by connecting Propeller’s digital health platform to two of Novartis’ medications. According to a release, Enerzair Breezhaler…
NorthStar Partners With IsoTherapeutics
NorthStar Medical Radioisotopes, along with Wilmette, Ill.-based Monopar Therapeautics, have partnered with IsoTherapeutics Group to develop and manufacture Radio-Immuno-Therapeutics (RITs) for the potential treatment of severe COVID-19, the company announced recently….
OnLume to Begin Clinical Trial
OnLume announced recently that it is beginning a clinical trial for its fluorescence-guided surgery (FGS) imaging device, which will be combined with a novel nerve-targeting agent. The Phase I-II study, which…
Promega Surpasses CSR Goals
Promega surpassed its environmental improvement goals set for the end of 2020 and achieved reductions in key sustainability metrics, according to its newly released Corporate Responsibility Report, the company announced…
Promega System to be Used by CDC
Promega’s Maxwell RNA Extraction System has been authorized for use in the CDC’s COVID-19 diagnostic testing protocol, the company announced today. The FDA granted the authorization on Monday. “This announcement…
Propeller to Co-Package with Asthma Med
Propeller Health will co-package the Propeller digital health platform with Novartis’ Enerzair Breezhaler, a recently approved medication developed to treat uncontrolled asthma, the company announced today. According to a release, the…
NorthStar, Monopar to Collaborate
NorthStar Medical Radioisotopes is collaborating with Monopar Therapeutics, a clinical-stage biopharmaceutical company, to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19, the company announced recently. “NorthStar will apply its expertise…
Exact Sciences’ GPS Test Proves to be Predictor
Exact Sciences‘ Oncotype DX Genomic Prostate Score (GPS) test is a strong independent predictor of critical outcomes in UFI-risk prostate cancer patients, the company announced today. The results of the study–which included 299…
Cellectar Announces $20M Public Offering
Cellectar Biosciences today announced the effective prices of $1.15 per share of common stock and one-half of a Series H Warrant of an underwritten public offering to raise approximately $20…
